However, we found obviously diminished SERPINA3 expression in patients compared with controls in the NAFLD and AS datasets, suggesting that SERPINA3 has an anti-NAFLD (35) and anti-AS (36) effects. The gene discussed is SERPINA3; the disease is metabolic dysfunction-associated steatotic liver disease.